

# CYTIP antibody - N-terminal region

Rabbit Polyclonal Antibody Catalog # AI14820

#### **Product Information**

Application WB Primary Accession 060759

Other Accession NM 004288, NP 004279

**Reactivity** Human, Mouse, Rat, Pig, Guinea Pig

**Predicted** Human, Mouse, Rat

Host Rabbit
Clonality Polyclonal
Calculated MW 40010

#### **Additional Information**

**Gene ID** 9595

Alias Symbol B3-1, CASP, CYBR, CYTHIP, HE, PSCDBP

Other Names Cytohesin-interacting protein, Cytohesin binder and regulator, CYBR,

Cytohesin-associated scaffolding protein, CASP, Cytohesin-binding protein HE, Cbp HE, Pleckstrin homology Sec7 and coiled-coil domains-binding protein,

CYTIP, PSCDBP

Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium

azide and 2% sucrose.

**Reconstitution & Storage** Add 50 ul of distilled water. Final anti-CYTIP antibody concentration is 1

mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at

20°C. Avoid repeat freeze-thaw cycles.

**Precautions** CYTIP antibody - N-terminal region is for research use only and not for use in

diagnostic or therapeutic procedures.

#### **Protein Information**

Name CYTIP

**Synonyms** PSCDBP

**Function** By its binding to cytohesin-1 (CYTH1), it modifies activation of ARFs by CYTH1

and its precise function may be to sequester CYTH1 in the cytoplasm.

**Cellular Location** Cytoplasm. Early endosome. Note=Recruited from the cytosol to endosomes


by SNX27

Expressed in lymph nodes, thymus, spleen, lung, peripheral blood leukocytes and bone marrow

### References

Tang P.,et al.Proc. Natl. Acad. Sci. U.S.A. 99:2625-2629(2002). Boehm T.,et al.EMBO J. 22:1014-1024(2003). Ota T.,et al.Nat. Genet. 36:40-45(2004). Hillier L.W.,et al.Nature 434:724-731(2005). Dixon B.,et al.Biochim. Biophys. Acta 1216:321-324(1993).

## **Images**



WB Suggested Anti-CYTIP Antibody Titration: 1.0 µg/ml Positive Control: Fetal Heart

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.